ADC · HER2+ 유방암

2개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab)

HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 91Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting